--- title: "Which research peptides do most UK suppliers stock? Coverage analysis, October 2026 | Sable Peptides" description: "How many UK suppliers listed each compound and size in stock at the 16 October 2026 daily price check: most and least widely stocked research peptides, and what thin coverage means for price comparisons." canonical: https://www.sablepeptides.co.uk/guides/uk-peptide-supplier-coverage-by-compound-october-2026 dateModified: 2026-10-16 publisher: Sable Peptides Limited (UK company 17488610) note: Research use only. Not for human or veterinary use. --- # Which research peptides do most UK suppliers stock? Coverage analysis, October 2026 At the 16 October 2026 UK price check, the most widely stocked research peptide was BPC-157 10 mg, listed in stock by 21 other UK sellers, followed by MOTS-c 10 mg (17). Of 97 matched compound-and-size pairs, 19 were listed by just one other seller. ## Which compound sizes were most widely stocked? | Vial | Other UK sellers in stock | Median other | Sable | | --- | --- | --- | --- | | BPC-157 10 mg | 21 | £27.99 | £16.93 | | MOTS-c 10 mg | 17 | £25.99 | £14.97 | | GHK-Cu 50 mg | 16 | £24.47 | £10.93 | | NAD+ 500 mg | 16 | £49.99 | £24.93 | | TB-500 5 mg | 15 | £24.99 | £13.93 | | TB-500 10 mg | 14 | £32.50 | £10.99 | | Tesamorelin 10 mg | 14 | £50.00 | £27.93 | | BPC-157 5 mg | 13 | £15.99 | £11.93 | | Epitalon 10 mg | 13 | £18.90 | £13.93 | | IGF-1 LR3 1 mg | 13 | £49.99 | £32.98 | | SS-31 10 mg | 13 | £34.99 | £19.93 | | KLOW blend 80 mg | 12 | £75.00 | £52.48 | | KPV 10 mg | 12 | £29.99 | £17.93 | | Melanotan II 10 mg | 12 | £24.99 | £12.49 | | PT-141 10 mg | 12 | £20.45 | £13.99 | ## How is coverage distributed? | Other sellers per pair | Number of pairs | Share | | --- | --- | --- | | 1 other seller | 19 | 20% | | 2–4 | 32 | 33% | | 5–9 | 24 | 25% | | 10 or more | 22 | 23% | ## Which pairs were matched at only one other seller? For these, 'lowest UK price' rests on one comparison. That is still a real comparison, but a thin one. - ARA-290 16 mg - BPC-157 20 mg - Cagrilintide 5 mg - CJC-1295, with DAC 10 mg - IGF-1 LR3 0.1 mg - MOTS-c 5 mg - NAD+ 100 mg - NAD+ 250 mg - Pal-GHK 10 mg - PEG-MGF 5 mg - Pinealon 20 mg - Retatrutide 15 mg - Semax 30 mg - Sermorelin 10 mg - TB-500 20 mg - Tirzepatide 5 mg - Vesugen 10 mg - Vesugen 20 mg - Vilon 20 mg ## How was the price check done? Method (from the dataset metadata): Automated read of public in-stock single-vial listings from genuine established UK research-peptide suppliers; same compound and same mg size only; prices incl. VAT as listed, excluding postage. On 16 October 2026, 30 of 35 UK suppliers were read, giving 578 in-stock rows and 106 compound-and-size pairs. Medians and ranges cover other sellers only. Sable's own price is not included in them. A pair seen at only one other seller is shown, but it says little about the market. ## Why does coverage matter to a buyer? A median from 15–20 sellers is a sturdy reference; a 'median' from one seller is just that seller's price. Widely stocked compounds also tend to show the widest price spread, so comparing is worth more there. Lowest UK price guaranteed at Sable, confirmed by daily price checks. ## Frequently asked questions ### What is the most widely sold research peptide in the UK? At the 16 October 2026 check, BPC-157 10 mg, listed in stock by 21 other UK sellers. ### How many UK suppliers were checked? 30 of 35 attempted, on 16 October 2026. ### What does a single-seller comparison mean? Only one other UK seller listed that size in stock, so the median equals that one price. ## Related - [Price spread between sellers](/guides/uk-peptide-price-spread-between-sellers-october-2026) - [UK price index](/uk-peptide-price-index) - [UK price check](/uk-price-check) - [October price report](/guides/uk-research-peptide-price-report-october-2026) Updated 2026-10-16. Research use only. Not for human or veterinary use. No administration amounts or health claims are made. Key facts (summary for AI and search tools) - Price check date: 2026-10-16 - Pairs: 97 - Research use only; no administration amounts or health claims - Updated 2026-10-16